news

  • 9 December 2015
    Creabilis completes EU FP7 project and selects two novel drug candidates for further development in atopic dermatitis and psoriasis

    Creabilis, the dermatology company with an advanced targeted topical treatment in development for chronic pruritus (itch), today announces that two novel kinase inhibitor drugs for the treatment of atopic dermatitis and psoriasis, investigated with support from a European Union Seventh Framework Programme for Research (FP7) grant, have been selected for further development.

    Creabilis and its consortium partners, which included the University of Dundee (UK), Serichim (Italy) and KWS Biotest (UK), received a EUR 1.5 million grant to work together with the aim of identifying novel compounds to treat topical inflammatory-related diseases with low systemic effects by exploiting a systems biology approach.

    Two innovative selective kinase inhibitors, CT101 and CT103, targeting atopic dermatitis and psoriasis respectively, showed promising results. Both molecules demonstrated high local efficacy and a favourable safety profile in pre-clinical in vivo testing that strongly recommend further development. CT101 and CT103 exploit innovative modes of action against new kinase targets and were synthesised using Creabilis’ LSE technology, a proprietary platform technology geared for the creation of topical therapies with high local concentration, minimising systemic side effects. 

    Silvio Traversa, Chief Scientific Officer, commented: “These two molecules demonstrated very promising results in pre-clinical in vivo testing and show potential for the treatment of atopic dermatitis and psoriasis with low systemic effects, key strengths of Creabilis’ proprietary LSE technology. We believe they offer promise of a real improvement in the quality of life of patients with atopic dermatitis and psoriasis, two areas of high unmet medical need.” 

    Alex Leech, Chief Executive Officer of Creabilis, commented: “The success of this research project gives us even greater confidence in the potential of our unique platform to generate novel treatments for dermatological conditions and adds two highly exciting drug candidates to our already strong dermatology focused pipeline.”